dmj

Supplementary Table 7. Multiple linear regression models for liver stiffness measurement according to u-ACR in insulin non-users (*n*=249)

Variable	Model 1		Model 2		Model 3		Model 4	
	STD β	*P* value	STD β	*P* value	STD β	*P* value	STD β	*P* value
u-ACR, mg/g Cr[a]	0.280	0.210	0.160	0.480	0.140	0.540	0.210	0.330
Age, yr	0.041	0.079	0.033	0.153	0.027	0.221	0.019	0.360
Male sex	−0.600	0.362	−0.66	0.301	−0.064	0.920	−0.23	0.70
BMI, kg/m²	0.240	0.005[b]	0.230	0.007[b]	0.130	0.170	0.11	0.230
Duration of diabetes, yr	−0.011	0.780	0.004	0.920	0.026	0.520	0.035	0.380
Hypertension			1.440	0.028[b]	1.520	0.021[b]	1.41	0.024[b]
Lipid medication			−1.73	0.003[b]	−1.590	0.01[b]	−1.84	0.002[b]
Triglyceride, mg/dL					−0.004	0.226	−0.003	0.320
ALT, IU/L					0.019	0.039[b]	0.019	0.024[b]
HOMA-IR, %					0.210	0.014[b]	0.210	0.060
HbA1c, %							0.046	0.830
HOMA-β							0.0001	0.940

Model 1 was adjusted for age, sex, BMI, and duration of diabetes; Model 2 adjusted for Model 1 parameters plus hypertension, lipid medication; Model 3 adjusted for Model 2 parameters plus triglyceride, ALT, HOMA-IR; Model 4 adjusted for Model 3 parameters plus HbA1c, HOMA-β.
u-ACR, urinary albumin to creatinine ratio; STD, standardized; BMI, body mass index; ALT, alanine aminotransferase; HOMA-IR, homeostasis model assessment of insulin resistance; HbA1c, glycosylated hemoglobin; HOMA-β, homeostasis model assessment-β.
[a]Statistical significance at *P*<0.05, [b]Log transformed form.